News | March 13, 2012

Asahi Kasei Acquires Zoll Medical

The AED Plus from Zoll

March 13, 2012 — Asahi Kasei Corp. and Zoll Medical Corp. jointly announced that Asahi Kasei will acquire Zoll for approximately $2.21 billion. The transaction has been approved by the boards of directors of both companies.

Asahi Kasei is a Japanese chemical manufacturer with businesses in the healthcare, chemicals and fibers, homes and construction materials, and electronics sectors. Zoll is a manufacturer of resuscitation, defibrillator-monitors and critical care devices and related software solutions.

The acquisition extends the development of Asahi Kasei’s “Health Care for Tomorrow” project, under which the company seeks to advance the development of new businesses through organic growth, targeted acquisitions, and strategic alliances. A key focus area of this effort is the resuscitation sector, an area where Zoll is already a market leader in the United States and has a strong international market presence. This transaction builds on the alliance between the two companies announced in July 2011, under which Asahi Kasei has exclusive rights to market and distribute Zoll’s AED Plus automated external defibrillator (AED) in Japan — the first AED in Japan with a function supporting cardiopulmonary resuscitation (CPR) that incorporates voice guidance and message displays.

Zoll’s comprehensive set of technologies helps clinicians, emergency medical technicians, and fire professionals treat victims in need of resuscitation and critical care. Zoll develops products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management. Its innovative product lines, which include LifeVest, the world’s only wearable automatic defibrillator; temperature management technologies for managing the core body temperature of critically ill or surgical patients; and AutoPulse, a revolutionary non-invasive cardiac support pump, represent significant potential drivers of growth for the company.

Commenting on the transaction, president & representative director of Asahi Kasei, Taketsugu Fujiwara, said, “We are very excited to be joining forces with Zoll, with whom we have enjoyed a productive partnership over the past nine months. In the medical devices business, the U.S. market leads the world, not only in size and scope, but also in technological innovation, so establishing a strong infrastructure in the U.S. is an important step for Asahi Kasei. This transaction will allow us to build on Zoll’s strong U.S. business position and its technology leadership, with Zoll forming the cornerstone of our critical care business. Together we will pursue new opportunities in the high-growth markets of Asia. We look forward to working with the management and all the employees of Zoll to develop a critical care business renowned worldwide for its ability to turn technological advances into sophisticated medical tools that save lives and deliver invaluable improvements in the quality of life of patients and their families.”

Richard A. Packer, CEO of Zoll, said, “We are delighted with this transaction and believe that it is in the best interest of our shareholders. In addition, we are convinced that Asahi Kasei’s ownership will create the right environment for Zoll and its team to continue transforming the science of resuscitation. We believe that Asahi Kasei will provide the right kind of support to help launch Zoll’s next phase of growth, and we are excited to be working together with Asahi Kasei. We expect all parts of Zoll to continue to thrive as part of Asahi Kasei.”

Asahi Kasei, through a U.S. subsidiary, will make a cash tender offer to purchase all of the outstanding shares of Zoll common stock for $93 per share. The purchase price represents a premium of 29.6 percent over Zoll’s volume weighted average closing stock price over the 30 trading day period ended March 9, 2012, and a 23.8 percent premium over the closing price on March 9, 2012. The tender offer is expected to commence within 10 business days and will remain open for a minimum of 20 business days. Closing of the tender offer is subject to customary conditions, including receipt of applicable regulatory clearances and the minimum tender of at least two-thirds of the outstanding shares of Zoll (on a fully diluted basis). The transaction is not subject to a financing condition. The Zoll board of directors has recommended that Zoll stockholders accept the offer and tender their shares into the offer when it is made. The transaction is expected to close in the second calendar quarter of 2012.

Following the completion of the tender offer, Asahi Kasei intends to implement a second-step merger pursuant to which all remaining shares of Zoll common stock not tendered in the offer will be converted into the right to receive the same cash price per share as in the offer. Upon completion of the merger, Zoll will become a wholly owned subsidiary within the Asahi Kasei Group, managed by the current Zoll management team and with all current business units and operations remaining intact. Zoll will also be delisted from the NASDAQ stock exchange at that time.

For more information: www.zoll.com, www.asahi-kasei.co.jp/asahi/en

Related Content

Zoll Canada Equipping Province of Québec Paramedic Services with X Series Monitor/Defibrillators
News | Defibrillator Monitors| October 16, 2017
October 16, 2017 — Zoll Canada, a subsidiary of Zoll Medical Corp., announced it has won the tender to equip all ambu
wearable defibrillators prevent sudden cardiac death in pediatric patients
Feature | Sudden Cardiac Arrest| May 11, 2017
May 11, 2017 — A new study shows that the use of a wearable cardioverter defibrillator (WCD) is safe and effective in
Physio-Control Launches HeartSine samaritan PAD 360P Automated External Defibrillator in United States
Technology | Defibrillator Monitors| April 24, 2017
Physio-Control announced April 19 that the company’s HeartSine samaritan PAD 360P (SAM 360P) fully automatic external...
AEDs, automated external defibrillators, requirements, U.S. schools, JACC study
News | Defibrillator Monitors| March 30, 2017
Automated external defibrillators (AEDs) are associated with increased survival of sudden cardiac arrest when installed...
Philips, FDA, class I recall, HeartStart MRx Monitor/Defibrillator
News | Defibrillator Monitors| March 28, 2017
Philips and the U.S. Food and Drug Administration (FDA) announced the company has initiated a recall of its HeartStart...
Zoll, Hospital Wearable Defibrillator, HWD, FDA premarket approval
Technology | Defibrillator Monitors| March 10, 2017
Zoll Medical Corp. announced that the company’s Hospital Wearable Defibrillator (HWD) has been granted premarket...
LifePak, AED, sudden cardiac arrest, defibrillator, automatic external defibrillator

A Physio-Control LifePak CR Plus defibrillator shown in use during a hand-off to paramedics, who use larger, more sophisticated defibrillator-monitors (behind gloved paramedic).

Feature | Sudden Cardiac Arrest| September 28, 2016 | Allied Market Research
Automated external defibrillators (AED) are portable and lightweight devices used to deliver an electric shock throug
sudden cardiac arrest, out-of-hospital, comatose patients, University of Arizona study, wake up
News | Sudden Cardiac Arrest| July 13, 2016
Physicians may be drawing conclusions too soon about survival outcomes of patients who suffered a cardiac arrest...
Zoll LifeVest wearable defibrillator, WEARIT-II Registry results, CardioStim EuroPace 2016
News | Defibrillator Monitors| June 21, 2016
Zoll Medical Corp. announced that patients experience a high one-year survival rate following use of the LifeVest...
Overlay Init